Literature DB >> 5425103

Dihydroxyphenylalanine (DOPA) in plasma during dopa treatment of patients with Parkinson's disease.

G M Tyce, M D Muenter, C A Owen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1970        PMID： 5425103

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN： 0025-6196            Impact factor:   7.616


× No keyword cloud information.
  6 in total

Review 1.  Levodopa: a review of its pharmacological properties and therapeutic use with particular reference to Parkinsonism.

Authors:  R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1971       Impact factor: 9.546

2.  [Dopa resorption and dopamin estimation in blood of patients with Parkinson's disease (author's transl)].

Authors:  E Metzel; W U Weitbrecht
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1974

3.  Treatment of Parkinson's disease with L-DOPA and decarboxylase inhibitor.

Authors:  U K Rinne; V Sonninen; T Sirtola
Journal:  Z Neurol       Date:  1972

Review 4.  Clinical pharmacokinetics of levodopa in parkinson's disease.

Authors:  J R Bianchine; G M Shaw
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

5.  Systemic activity of orally administered L-dopa in the elderly Parkinson patient.

Authors:  M A Evans; E J Triggs; G A Broe; N Saines
Journal:  Eur J Clin Pharmacol       Date:  1980       Impact factor: 2.953

6.  The effect of low dose carbidopa/levodopa on prolactin and growth hormone concentrations in patients with breast cancer and in benign breast tumours.

Authors:  M K Jones; I D Ramsay; P G Jenner
Journal:  Br J Clin Pharmacol       Date:  1978-05       Impact factor: 4.335
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.